| All patients | Absence of substantial viability |  | Substantial Viability |  | ||
---|---|---|---|---|---|---|---|
 | (n = 193) | All patients (n = 86) | LVEF < median (n = 43) | LVEF > median (n = 43) | P1 | (n = 107) | P2 |
Age, years | 70 (63-75) | 69 (59-76) | 69 (61-76) | 66 (59-76) | 0.534 | 70 (65-75) | 0.283 |
Male sex | 167 (87%) | 77 (90%) | 37 (86%) | 40 (93%) | 0.291 | 90 (84%) | 0.273 |
BMI (kg/m2) | 28 (25-31) | 27 (25-31) | 29 (25-32) | 26 (24-30) | 0.111 | 28 (25-31) | 0.773 |
Systolic blood pressure mmHg) | 123 (111-140) | 132 (110-148) | 117 (102-145) | 136 (123-149) | 0.002 | 120 (111-134) | 0.084 |
Diastolic blood pressure (mmHg) | 73 (65-80) | 74 (64-84) | 72 (61-80) | 74 (66-86) | 0.296 | 72 (65-80) | 0.641 |
Heart rate (bpm) | 65 (59-75) | 63 (58-70) | 64 (58-74) | 62 (57-68) | 0.308 | 66 (59-76) | 0.057 |
NYHA classification | Â | Â | Â | Â | 0.022 | Â | 0.357 |
NYHA class I | 32 (17%) | 12 (14%) | 3 (14%) | 9 (21%) | Â | 20 (19%) | Â |
NYHA class II | 124 (64%) | 60 (70%) | 29 (67%) | 31 (72%) | Â | 64 (60%) | Â |
NYHA class III | 37 (19%) | 14 (16%) | 11 (26%) | 3 (7%) | Â | 23 (21%) | Â |
Previous infarct | 129 (67%) | 62 (72%) | 34 (79%) | 28 (65%) | 0.149 | 67 (63%) | 0.165 |
Previous revascularisation | 71 (37%) | 29 (34%) | 15 (35%) | 14 (33%) | 0.820 | 42 (40%) | 0.428 |
Co-morbidities: | Â | Â | Â | Â | Â | Â | Â |
History of hypertension | 56 (29%) | 24 (28%) | 10 (23%) | 14 (33%) | 0.336 | 32 (30%) | 0.761 |
Diabetes mellitus | 36 (19%) | 13 (15%) | 5 (12%) | 8 (19%) | 0.366 | 23 (22%) | 0.258 |
Medications: | Â | Â | Â | Â | Â | Â | Â |
β-blockers | 167 (87%) | 82 (95%) | 42 (98%) | 40 (93%) | 0.306 | 85 (79%) | 0.001 |
RAAS inhibitors | 175 (91%) | 83 (97%) | 41 (95%) | 42 (98%) | 0.557 | 92 (86%) | 0.012 |
Diuretics | 130 (67%) | 55 (64%) | 30 (70%) | 25 (58%) | 0.261 | 75 (70%) | 0.366 |
Spironolactone | 53 (28%) | 21 (24%) | 16 (37%) | 5 (12%) | 0.006 | 32 (30%) | 0.396 |
Digoxin | 18 (9%) | 6 (7%) | 4 (9%) | 2 (5%) | 0.397 | 12 (10%) | 0.314 |
CMR measurements | Â | Â | Â | Â | Â | Â | Â |
LVEF | 34 (27-43) | 41 (29-51) | 29 (24-38) | 50 (45-57) | Â | 31 (24-35) | < 0.0001 |
LVEDV index | 117 (95-150) | 103 (84-127) | 126 (101-155) | 91 (69-104) | < 0.0001 | 129 (111-156) | < 0.0001 |
LVESV index | 78 (55-110) | 57 (41-83) | 82 (69-113) | 42 (32-54) | < 0.0001 | 89 (72-117) | < 0.0001 |
LVMM index | 82 (71-101) | 80 (68-97) | 91 (73-106) | 75 (65-84) | 0.002 | 85 (74-101) | 0.120 |
Segmental analysis | Â | Â | Â | Â | Â | Â | Â |
Segments | 3281 | 1462 | 731 | 731 | Â | 1819 | Â |
Dysfunctional Segments | 1759 (53%) | 527 (36%) | 154 (21%) | 373 (51%) | < 0.0001 | 1232 (68%) | Â |
Dysfunctional segments without LGE | 581 (18%) | 31 (2%) | 14 (2%) | 17 (2%) | 0.884 | 550 (30%) | Â |
Dysfunctional segments with LGE | 1178 (36%) | 496 (34%) | 140 (19%) | 356 (49%) | < 0.0001 | 682 (37%) | Â |
Dysfunctional segments with > 50% LGE | 559 (17%) | 313 (21%) | 65 (9%) | 248 (34%) | < 0.0001 | 246 (14%) | Â |
Segments with normal function - no LGE | 1326 (40%) | 849 (58%) | 513 (70%) | 336 (46%) | < 0.0001 | 477 (26%) | Â |
Segments with normal function and LGE | 98 (3%) | 43 (3%) | 32 (4%) | 11 (2%) | 0.283 | 55 (3%) | Â |